Encouraging results are reported in this issue of the Journalfor an oral drug for use in the battle against visceral leishmaniasisin India (pages 1739–1746). Given the hurdles that typicallystymie the development of drugs for diseases endemic primarilyto impoverished regions, the story of miltefosine may offera model for future successes.
In Bihar, in northeastern India, with 83 million residents whoare among the poorest and least educated people in the country,as many as 200,000 deaths from visceral leishmaniasis occureach year. Nearly everyone in this region of India has watcheda neighbor or family member . . . [Full Text of this Article]
Previous
